Amdipharm signs lease at One Gateway

Amdipharm signs lease at One Gateway

9/09/2009 | feat. in The Irish Times & Irish Independent

Amdipharm Limited, has taken a ten-year lease on 266sq.m on part fourth floor of the scheme. The rent was agreed at approx. €258psm on the fully fitted suite. The firm joins: Freightwatch Group, Colt Telecom, CPM Architecture & Engineering and developers Collen Group.

Located on East Wall Road in the heart of Dublin’s north Docklands the Gateway development comprises approx. 16,000 sq.m. of office accommodation spanning three impressive buildings. The scheme is convenient to the Dart, mainline rail, Dublin Bus, the Luas and Port Tunnel, offering direct access to the M1/M50 and Dublin Airport.

Paddy Jordan of Collen Group, commented “the letting again highlights the high specification of the entire Gateway development, coupled with the value for money on offer versus nearby Dublin 1 & 2 developments, many of which are inferior”.

Bryan Evans, Director of Amdipharm Limited, added “Having decided to expand our footprint in Ireland, Amdipharm needed suitable premises with good communication links at the right price. One Gateway fulfils all of those needs”.

David Bennett of DTZ advised the tenant, while Justin McCarthy of Jones Lang LaSalle acted for Collen Group.

Additional floors / fully fitted suites are available from approx. €209psm, while purchase options are available at neighbouring Three Gateway also. Prime the centrepiece of the hugely successful development has been designed to meet the most demanding requirements expected of a corporate headquarters and comprises approx. 7,228sq.m. Secure underground car parking is available throughout the scheme.

Further information on the Gateway development is available from Jones Lang LaSalle 01-6731600, Savills 01-6181300 or CBRE 01-6185500.

Amdipharm Limited is the Irish representative of Waymade International Holdings Limited a privately owned global pharmaceutical business focused on providing medicines that meet real clinical need. For further information please visit (www.amdipharm.com).

 

[ back ]